Anastasis

A day's supply. The vial is single use and expires after 24h. Max dose is two and a half vials per day. So anywhere from let's call it $40-80k per year. Plus the hardware.

My understanding after reading a bit is that active ingredients are highly soluble prodrug formulations (after absorption the body metabolizes the prodrug foslevodopa into the drug levodopa by chopping off the "fos"). So not exactly the old treatment, but with just a very minor molecular tweak to make the subcutaneous infusion viable. Not sure how any of that shakes out wrt the patents. It's a $62k/year drug in Canada. Not sure what pricing concessions NHS got, but it would probably be in the six figures range in the US.

Yeah, that's a pretty cool before/after shot. Not really a new drug though, a new delivery mechanism (infusion) that smooths out the on/off effects. The active ingredients are basically the same as what PD has been treated with for decades (levodopa/carbidopa). Video is probably a bit misleading in terms of differentiating this from existing treatments. You can see the same short-term effects with administration of simple oral levo/carbidopa. The differentiator appears to the be the increase in on time and the reduction in off time over extended periods with the infusion. Balanced by greater frequency of side effects and side effect related treatment discontinuation. I think that the FDA eventually approves it as the hang up appears to be manufacturing. Would be more interesting to compare it head up to extended release orals and/or the GI administered form. The real advance here appears to be that compared to the GI infusion this doesn't require surgical placement. Findings Between Oct 19, 2020, and Sept 29, 2021, of 270 participants screened and 174 enrolled, 141 were randomly assigned and received continuous subcutaneous infusion of foslevodopa-foscarbidopa plus oral placebo capsules (n=74) or oral encapsulated immediate-release levodopa-carbidopa plus continuous subcutaneous infusion of placebo solution (n=67). Compared with levodopa-carbidopa, foslevodopa-foscarbidopa showed a significantly greater increase in on time without troublesome dyskinesia (model-based mean [SE] 2·72 [0·52] vs 0·97 [0·50] h; difference 1·75 h, 95% CI 0·46 to 3·05; p=0·0083) and a significantly greater reduction in off time (−2·75 [0·50] vs −0·96 [0·49] h; difference −1·79 h, −3·03 to −0·54; p=0·0054). Hierarchical testing ended after the first secondary endpoint. Adverse events were reported in 63 (85%) of 74 patients in the foslevodopa-foscarbidopa group versus 42 (63%) of 67 in the levodopa-carbidopa group, and incidences of serious adverse events were similar between the groups (six [8%] of 74 vs four [6%] of 67, respectively). The most frequent adverse events in the foslevodopa-foscarbidopa group were infusion site adverse events (erythema 20 [27%]), pain 19 [26%]), cellulitis (14 [19%]), and oedema (nine [12%]), most of which were non-serious and mild–moderate in severity. The only system organ class that had more than one serious adverse event in the foslevodopa-foscarbidopa group was infections and infestations (catheter site cellulitis [one [1%]] and infusion site cellulitis [one [1%]). Adverse events led to premature discontinuation of study drug in 16 (22%) of 74 participants in the foslevodopa-foscarbidopa group versus one (1%) of 67 participants in the oral levodopa-carbidopa group.

Any idea how many man-hours?

eform timeline update form 4, trust, via silencershop purchased 02/2024 certified 03/06/2024 approved 08/27/2024 About half as long as my first one, IIRC.

I was wondering why they were the last place on earth to roll out tap to pay.

That mother fucking foil lined sleeve you had to put the hot pocket in was my easy bake oven.

They break kids out after 9th grade into vocational and secondary track. I think that makes a lot of sense.

Btw. She misses by a few months according even to the census bureau.

Feel free. But you know it’s true.

Nope. She does bear some of the hallmarks in her life story. However. She was 21 when the NES dropped. Not gen x.

Booster news.

CSPAN running the benedictions. Y'all getting that on CNN feeds?

keep on rocking in the free world!

And with less arming genocide.

Like what are the qualification to be a US senator, cause that bar seems really low.

Was that rule of three compliant?

Pete B would have placed higher than KH in level D primary.

I think that I criticized their clown shown equally, and at least if we standardize for pushback.

Nobody likes a quitter.

Loyalty to the constitution as a first principle would be nice.

Oprah approaches obama level.

That thread appears special, granted.